The two most talked-about GLP-1based options for weight management are: Semaglutide a GLP-1 medication that has been used for both diabetes and weight loss
This cardiovascular outcomes trial of semaglutide versus placebo in patients with type 2 diabetes at high cardiovascular risk revealed an unexpected finding: patients receiving semaglutide experienced a statistically significant increase in diabetic retinopathy complications (hazard ratio 1.76, 95% CI 1.112.78, p=0.02)
Wegovy (semaglutide) With the same active ingredient as Ozempic, semaglutide, Wegovy is FDA-approved for chronic weight management and to reduce the risk of major adverse cardiovascular events
Pharmaceutical companies are actively expanding obesity-focused clinical programs and commercial strategies
When Covid happened, [suddenly] everyone looked in the mirror and was like, I need to take care of my health
rskov C, Poulsen SS, Mller M, Holst JJ: Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
